|
The utility of the Ion Torrent PGM next generation sequencing for analysis of the most commonly mutated genes among patients with colorectal cancer in India
Simmi Mehra1, Aseem Kumar Tiwari1, Swati Pabbi Mehta1, Ritesh Sachdev2, Chhavi Rajvanshi1, Rajni Chauhan1, Abhishek Saini1, Ashok Vaid3
1 Molecular and Transplant Immunology Laboratory, Department of Transfusion Medicine, Gurgaon, Haryana, India
2 Department of Histopathology, Medanta-The Medicity, Gurgaon, Haryana, India
3 Department of Medical and Haemato Oncology, Medanta-The Medicity, Gurgaon, Haryana, India
Correspondence Address:
Aseem Kumar Tiwari,
Molecular and Transplant Immunology Laboratory, Department of Transfusion Medicine, Gurgaon, Haryana
India
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijc.IJC_723_19 PMID: 33753628
Background: The requirement for the mutation analysis for Kirsten rat sarcoma viral oncogene (KRAS) in colorectal cancer (CRC) is rapidly increasing as it is a predictive biomarker and also, its absence signifies response to anti-epidermal growth factor receptor (anti-EGFR) antibody treatment. The aim of our study was to investigate the pathological diagnosis and distribution of KRAS mutations in colorectal cancer with the use of next generation sequencing platform (Ion Torrent).
Methods: A total of 56 CRC samples were tested to identify the genetic mutations, especially KRAS using the primers which included ~2800 COSMIC mutations of 50 oncogenes. Ion Torrent personal genome machine (semiconductor-based sequencing) was used for the sequencing and analysis. Along with KRAS, other 49 genes were also studied for COSMIC mutations.
Results: KRAS mutation 25 (44.6%) had the highest frequency, followed by TP53 10 (17.9%) and PIK3CA mutation 4 (7.1%). Of all the KRAS mutations identified, mutations in codon 12 were most frequent followed by mutations in codon 13 and 61. The most frequent substitution was glycine to aspartate mutation in codon 12 (p.Gly12Asp) followed by glycine to valine (p.Gly12Val). Combinations of mutations were also studied. Our study revealed that seven cases (12.5%) had both KRAS and TP53 mutations (highest of all the combinations).
Conclusion: The analysis of KRAS mutation frequency and its mutational subtype analysis in human CRCs by using semiconductor-based platform in routine clinical practices have been performed in Indian population. The findings were similar to earlier published reports from the Western literature.
|
